ORIC Projected Dividend Yield
Oric Pharmaceuticals Inc ( NASDAQ : ORIC )ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company. Co.'s clinical stage product candidates include: ORIC-533, an orally bioavailable small molecule inhibitor of CD73 which playing a role in resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-114, a brain penetrant, orally bioavailable, irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; and ORIC-944, an allosteric inhibitor of polycomb repressive complex 2 via the embryonic ectoderm development subunit. 20 YEAR PERFORMANCE RESULTS |
ORIC Dividend History Detail ORIC Dividend News ORIC Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |